Redhawk Wealth Advisors Inc. Acquires 272 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Redhawk Wealth Advisors Inc. lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,891 shares of the company’s stock after acquiring an additional 272 shares during the period. Redhawk Wealth Advisors Inc.’s holdings in Medpace were worth $1,625,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in MEDP. Stone House Investment Management LLC purchased a new stake in Medpace in the third quarter worth $33,000. Ashton Thomas Securities LLC purchased a new position in Medpace during the 3rd quarter valued at about $37,000. Capital Performance Advisors LLP bought a new stake in shares of Medpace during the third quarter valued at about $46,000. True Wealth Design LLC lifted its holdings in shares of Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after buying an additional 168 shares in the last quarter. Finally, UMB Bank n.a. increased its holdings in shares of Medpace by 191.4% in the third quarter. UMB Bank n.a. now owns 271 shares of the company’s stock worth $90,000 after purchasing an additional 178 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on MEDP shares. Redburn Atlantic started coverage on shares of Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective on the stock. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Truist Financial decreased their target price on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Finally, StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $380.56.

Medpace Trading Up 1.3 %

Shares of NASDAQ:MEDP opened at $335.23 on Thursday. Medpace Holdings, Inc. has a 52 week low of $277.72 and a 52 week high of $459.77. The company has a market cap of $10.42 billion, a PE ratio of 29.35, a P/E/G ratio of 1.80 and a beta of 1.36. The company’s 50 day moving average is $341.36 and its two-hundred day moving average is $358.26.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.22 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.